Why aren’t more people taking Paxlovid for COVID-19?

The antiviral treatment for COVID-19 is known for its effectiveness in reducing severe outcomes like hospitalization and death. Despite being recommended for certain high-risk groups, factors such as high cost, doctor's reluctance to prescribe and complex reimbursement processes have hindered its widespread use.

The drug, initially free, now comes with a hefty price tag of $1,390, deterring some patients and doctors. Issues like potential drug interactions and the availability of alternative treatments also contribute to the low uptake of Paxlovid. 

Read more: The Associated Press

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.

© 2023 American Dental Association